NSE: TORNTPHARM · BSE: 500420 · ISIN INE685A01028
Torrent Pharmaceuticals Limited stock analysis
Torrent Pharmaceuticals Limited ranks #876 in the TickerSutra evidence-ranked universe with a score of 59/100 and 95% data confidence. The latest captured fundamentals show ROCE of 15.2%, quarterly sales growth of 54.9% and quarterly profit growth of 5.8%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Debt/equity is above 0.5×
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹8,508cr | ₹2,431cr | ₹777cr | 29.0% |
| 2023 | ₹9,620cr | ₹2,842cr | ₹1,245cr | 30.0% |
| 2024 | ₹10,728cr | ₹3,368cr | ₹1,656cr | 31.0% |
| 2025 | ₹11,516cr | ₹3,721cr | ₹1,911cr | 32.0% |
| 2026 | ₹13,980cr | ₹4,558cr | ₹2,138cr | 33.0% |
| TTM | ₹15,723cr | ₹5,191cr | ₹2,156cr | 33.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Torrent Pharmaceuticals Limited has informed the Exchange about Acquisition - Disclosure pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )
RoutineTrading WindowNSE · 28 Sept 2026Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineTorrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · 11 Sept 2026Intimation of Schedule of Investor Meets
RoutineSecurity Cover CertificateNSE · 10 Sept 2026IDBI Trusteeship Services Limited has informed the exchange for Torrent Pharmaceuticals Limited regarding Security Cover Certificate of ISIN INE685A07082 for Q1 for the FY 2026-2027
RoutineCopy of Newspaper PublicationNSE · 9 Sept 2026Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares
MANAGEMENT COMMENTARY
Signals from filed documents
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…